Juan G Sierra-Madero1, Susan Ellenberg2, Mohammed S Rassool3, Ann Tierney2, Pablo F Belaunzarán-Zamudio1, Alondra López-Martínez1, Alicia Piñeirúa-Menéndez1, Luis J Montaner4, Livio Azzoni4, César Rivera Benítez5, Irini Sereti6, Jaime Andrade-Villanueva7, Juan L Mosqueda-Gómez8, Benigno Rodriguez9, Ian Sanne10, Michael M Lederman9. 1. Departmento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán". Vasco de Quiroga 15, Col. Sección XVI, Del. Tlalpan. México DF, México. CP 14000. 2. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine. 611 Blockley Hall. 423 Guardian Drive, Philadelphia, PA 19104-602. USA. 3. Clinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of Witwatersrand. Perth Ave, Westdene. Johannesburg, South Africa. 4. HIV-1 Immunopathogenesis Laboratory, The Wistar Institute. 3601 Spruce Street, Philadelphia, PA 19104. USA. 5. Servicio de Infectología, Hospital General de México, Dr. Balmis 148, Col. Doctores. México DF, México. CP 06726. 6. HIV Pathogenesis Unit, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases/National Institutes of Health. 10 Center Drive, Building 10, 11C-103. Bethesda, MD 20892. 7. Unidad de VIH, Hospital Civil de Guadalajara. Calle Hospital 278 S.H. Col. Alcalde Barranquitas. Guadalajara, Jalisco, México. CP 44280. 8. Centro de Ambulatorio de Prevención y Atención en SIDA e Infecciones de Transmisión Sexual León. Calle 20 de enero # 927, Col. Obregón. León, Guanajuato, México CP 37000. 9. Center for AIDS Research, Case Western Reserve University. 2061 Cornell Rd, Cleveland OH 44106. USA. 10. Clinical HIV Research Unit, Department of Internal Medicine, Faculty of Health Sciences, University of Witwatersrand. Perth Ave, Westdene. Johannesburg, South Africa ; Center for International Development, Boston University. USA.
Abstract
BACKGROUND:Immune Reconstitution Inflammatory Syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in HIV-infected patients. IRIS is associated with an increased risk of hospitalization and death. We ascertained whether CCR5 blockade using maraviroc reduces the risk of IRIS. METHODS: The CADIRIS study was a randomized, double-blind, placebo-controlled, clinical trial that accrued subjects from five clinical sites in Mexico and one in South Africa between November 2009 and January 2012, and followed them for one year. The primary outcome was occurrence of IRIS by 24 weeks. HIV-infected adults, naïve to ART, with CD4 cells <100/μL, and HIVRNA >1,000 copies/mL were eligible. We screened 362 subjects; 279 met inclusion criteria, 3 refused participation, and 276 were randomized. Participants received maraviroc 600 mg twice daily or placebo added to an ART regimen that included tenofovir, emtricitabine, and efavirenz for 48 weeks. FINDINGS: There were 276 patients randomized (140 receivedmaraviroc and 136 placebo). There was no difference in the time to IRIS events between treatment arms (HR 1·08, 95% CI (0·66, 1·77), log-rank test p=0·743). In total, 64 (23%) patients had IRIS events, 33 (24%) in the maraviroc arm and 31 (23%) in the placebo arm (p=0·88). INTERPRETATION: Maraviroc had no significant effect on frequency, time or severity of IRIS events after ART initiation. Including a CCR5 inhibitor in an initial treatment regimen does not confer a meaningful protection from the occurrence of IRIS in persons with advanced HIV infection. FUNDING: The trial was funded as investigator initiated research by Pfizer Inc, New York, NY, USA. TRIAL REGISTRATION: ClinicalTrials.gov. ID: NCT00988780 (http://clinicaltrials.gov/ct2/show/NCT00988780).
RCT Entities:
BACKGROUND: Immune Reconstitution Inflammatory Syndrome (IRIS) is a common complication of antiretroviral therapy (ART) in HIV-infectedpatients. IRIS is associated with an increased risk of hospitalization and death. We ascertained whether CCR5 blockade using maraviroc reduces the risk of IRIS. METHODS: The CADIRIS study was a randomized, double-blind, placebo-controlled, clinical trial that accrued subjects from five clinical sites in Mexico and one in South Africa between November 2009 and January 2012, and followed them for one year. The primary outcome was occurrence of IRIS by 24 weeks. HIV-infected adults, naïve to ART, with CD4 cells <100/μL, and HIVRNA >1,000 copies/mL were eligible. We screened 362 subjects; 279 met inclusion criteria, 3 refused participation, and 276 were randomized. Participants received maraviroc 600 mg twice daily or placebo added to an ART regimen that included tenofovir, emtricitabine, and efavirenz for 48 weeks. FINDINGS: There were 276 patients randomized (140 received maraviroc and 136 placebo). There was no difference in the time to IRIS events between treatment arms (HR 1·08, 95% CI (0·66, 1·77), log-rank test p=0·743). In total, 64 (23%) patients had IRIS events, 33 (24%) in the maraviroc arm and 31 (23%) in the placebo arm (p=0·88). INTERPRETATION:Maraviroc had no significant effect on frequency, time or severity of IRIS events after ART initiation. Including a CCR5 inhibitor in an initial treatment regimen does not confer a meaningful protection from the occurrence of IRIS in persons with advanced HIV infection. FUNDING: The trial was funded as investigator initiated research by Pfizer Inc, New York, NY, USA. TRIAL REGISTRATION: ClinicalTrials.gov. ID: NCT00988780 (http://clinicaltrials.gov/ct2/show/NCT00988780).
Authors: Philip M Grant; Lauren Komarow; Janet Andersen; Irini Sereti; Savita Pahwa; Michael M Lederman; Joseph Eron; Ian Sanne; William Powderly; Evelyn Hogg; Carol Suckow; Andrew Zolopa Journal: PLoS One Date: 2010-07-01 Impact factor: 3.240
Authors: Julian H Elliott; Khol Vohith; Sarun Saramony; Chin Savuth; Chan Dara; Chel Sarim; Sarah Huffam; Robert Oelrichs; Pouv Sophea; Vonthanak Saphonn; John Kaldor; David A Cooper; Mean Chhi Vun; Martyn A French Journal: J Infect Dis Date: 2009-12-01 Impact factor: 5.226
Authors: Anne Bourgarit; Guislaine Carcelain; Valerie Martinez; Caroline Lascoux; Veronique Delcey; Brigitte Gicquel; Eric Vicaut; Philippe H Lagrange; Daniel Sereni; Brigitte Autran Journal: AIDS Date: 2006-01-09 Impact factor: 4.177
Authors: Thomas B Campbell; Laura M Smeaton; N Kumarasamy; Timothy Flanigan; Karin L Klingman; Cynthia Firnhaber; Beatriz Grinsztejn; Mina C Hosseinipour; Johnstone Kumwenda; Umesh Lalloo; Cynthia Riviere; Jorge Sanchez; Marineide Melo; Khuanchai Supparatpinyo; Srikanth Tripathy; Ana I Martinez; Apsara Nair; Ann Walawander; Laura Moran; Yun Chen; Wendy Snowden; James F Rooney; Jonathan Uy; Robert T Schooley; Victor De Gruttola; James Gita Hakim Journal: PLoS Med Date: 2012-08-14 Impact factor: 11.069
Authors: Dona L Fleishaker; Juan A Garcia Meijide; Andriy Petrov; Michael David Kohen; Xin Wang; Sujatha Menon; Thomas C Stock; Charles A Mebus; James M Goodrich; Howard B Mayer; Bernhardt G Zeiher Journal: Arthritis Res Ther Date: 2012-01-17 Impact factor: 5.156
Authors: Graeme Meintjes; Katalin Andrea Wilkinson; Molebogeng Xheeda Rangaka; Keira Skolimowska; Kerryn van Veen; Musaed Abrahams; Ronnett Seldon; Dominique J Pepper; Kevin Rebe; Priscilla Mouton; Gilles van Cutsem; Mark Patrick Nicol; Gary Maartens; Robert John Wilkinson Journal: Am J Respir Crit Care Med Date: 2008-08-28 Impact factor: 21.405
Authors: Emily B Wong; Tanvier Omar; Gosetsemang J Setlhako; Regina Osih; Charles Feldman; David M Murdoch; Neil A Martinson; David R Bangsberg; W D F Venter Journal: PLoS One Date: 2012-10-16 Impact factor: 3.240
Authors: Laura W Musselwhite; Bruno B Andrade; Susan S Ellenberg; Ann Tierney; Pablo F Belaunzaran-Zamudio; Adam Rupert; Michael M Lederman; Ian Sanne; Juan G Sierra Madero; Irini Sereti Journal: EBioMedicine Date: 2016-01-14 Impact factor: 8.143
Authors: Maura Manion; Bruno B Andrade; Rebecca DerSimonian; Wenjuan Gu; Adam Rupert; Laura W Musselwhite; Juan G Sierra-Madero; Pablo F Belaunzaran-Zamudio; Ian Sanne; Michael M Lederman; Irini Sereti Journal: J Virus Erad Date: 2017-01-01
Authors: Carson M Quinn; Victoria Poplin; John Kasibante; Kyle Yuquimpo; Jane Gakuru; Fiona V Cresswell; Nathan C Bahr Journal: Life (Basel) Date: 2020-10-29
Authors: Caian L Vinhaes; Mariana Araujo-Pereira; Rafael Tibúrcio; Juan M Cubillos-Angulo; Fernanda O Demitto; Kevan M Akrami; Bruno B Andrade Journal: Life (Basel) Date: 2021-01-18
Authors: Olga P Frolova; Olga V Butylchenko; Patimat G Gadzhieva; Margarita Yu Timofeeva; Valeria A Basangova; Vladislava O Petrova; Inna A Fadeeva; Maria I Kashutina; Nadezhda N Zabroda; Artem A Basov; Elena V Belova; Yury V Zhernov; Oleg V Mitrokhin; Inga I Enilenis; Lyudmila P Severova Journal: Trop Med Infect Dis Date: 2022-05-31